Clinical Trial

Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus Venetoclax

Name: Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus Venetoclax — clinical trial record (NCT07407660)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

This study aims to compare the efficacy and safety of a shortened treatment course based on the bone marrow blast count on Day 14 versus standard treatment in patients with acute myeloid leukemia treated with venetoclax plus azacitidine.

Trial Details

NCT Number	NCT07407660
Lead Sponsor	Peking University People's Hospital Collaborators: Shanghai Qianzhanruiji Enterprise Consulting Co., Ltd.
Conditions	Acute Myeloid Leukemia
Enrollment	250 participants
Start Date	2026-02-01
Primary Completion	2028-02-01 (estimated)
Study Completion	2030-02-01 (estimated)
Updated on ClinicalTrials.gov	2026-02-12